<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193047</url>
  </required_header>
  <id_info>
    <org_study_id>1002-039</org_study_id>
    <nct_id>NCT03193047</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg QD When Added to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if bempedoic acid (ETC-1002) 180mg added to PCSK9
      inhibitor (evolocumab) therapy is effective and safe in patients with elevated LDL
      cholesterol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Actual">February 19, 2018</completion_date>
  <primary_completion_date type="Actual">January 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change of low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Assess the 2-month efficacy of bempedoic acid 180 mg/day vs placebo in the reduction of LDL-C in patients on PCSK9i therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change of low-density lipoprotein cholesterol (LDL-C)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>Assess the 1-month efficacy of bempedoic acid 180 mg/day vs placebo in the reduction of LDL-C in patients on PCSK9i therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of apolipoprotein B (ApoB), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), and high-sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>Baseline, 4 weeks, and 8 weeks</time_frame>
    <description>Evaluate the effect of bempedoic acid 180 mg/day vs placebo on ApoB, non-HDL-C, TC, and hs-CRP after 1 and 2 months in patients on PCSK9i therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>Baseline through 8 weeks</time_frame>
    <description>Evaluate the safety and tolerability of bempedoic acid 180 mg/day compared to placebo in patients on PCSK9i therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>bempedoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bempedoic acid 180mg</intervention_name>
    <description>Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy</description>
    <arm_group_label>bempedoic acid</arm_group_label>
    <other_name>ETC-1002</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evolocumab</intervention_name>
    <description>Monthly PCSK9i (evolocumab) background therapy</description>
    <arm_group_label>bempedoic acid</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years or legal age of majority depending on regional law

          -  Fasting, calculated LDL-C at screening ≥160 mg/dL

          -  Men and nonpregnant, nonlactating women

        Exclusion Criteria:

          -  Heterozygous (HeFH) or Homozygous (HoFH) Familial Hypercholesterolemia

          -  Total fasting TG ≥500 mg/dL

          -  Renal dysfunction or a glomerulonephropathy; eGFR &lt;30 mL/min/1.73 m2

          -  Known cardiovascular disease (CVD), peripheral arterial disease (PAD), or
             cerebrovascular disease (CD)

          -  History of type 1 or type 2 diabetes

          -  Uncontrolled hypertension

          -  Uncontrolled hypothyroidism

          -  Liver disease or dysfunction

          -  Gastrointestinal conditions or procedures (including Lap-Band® or gastric bypass)

          -  History of hematologic or coagulation disorders

          -  History of malignancy (except non-metastatic basal or squamous cell carcinoma of the
             skin and cervical carcinoma in situ)

          -  Unexplained creatine kinase (CK) &gt;3 × ULN

          -  Use of a cholesterylester transfer protein (CETP) inhibitor in the last 12 months
             prior to screening, such as: anacetrapib, dalcetrapib, or evacetrapib

          -  Pregnant or breast feeding, or planning to become pregnant during treatment and/ or
             within 30 days after the end of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Nash, MD</last_name>
    <role>Study Director</role>
    <affiliation>Esperion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.who.int/mediacentre/factsheets/fs317/en/</url>
    <description>World Health Organization Fact Sheet No. 317</description>
  </link>
  <reference>
    <citation>Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PH, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457.</citation>
    <PMID>27892461</PMID>
  </reference>
  <reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45. doi: 10.1161/01.cir.0000437738.63853.7a. Epub 2013 Nov 12. Erratum in: Circulation. 2015 Dec 22;132(25):e396. Circulation. 2014 Jun 24;129(25 Suppl 2):S46-8.</citation>
    <PMID>24222016</PMID>
  </reference>
  <reference>
    <citation>Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108-13.</citation>
    <PMID>11535564</PMID>
  </reference>
  <reference>
    <citation>Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003 Apr 2;289(13):1681-90. Review.</citation>
    <PMID>12672737</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <disposition_first_submitted>April 30, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 2, 2018</disposition_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>PCSK9</keyword>
  <keyword>Repatha</keyword>
  <keyword>evolocumab</keyword>
  <keyword>LDL-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

